lyophilisation raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
| Property | Value | Notes |
|---|---|---|
| Molecular weight, DAC form | About 3647 Da | Varies with salt form |
| Molecular weight, non-DAC form | About 3358 Da | MOD GRF(1-29) |
| Solubility class | Water soluble | Also dissolves in polar solvents |
| Reported half-life, DAC form | About five to eight days | Values from human studies |
| Common synonyms | CJC-1295; MOD GRF(1-29) | Name depends on variant |
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
== Function == Because NADP(H), which exists in oxidized (NADP+) and reduced (NADPH) forms, cannot cross the mitochondrial membrane, eukaryotic cells maintain separate cytosolic and mitochondrial NADP(H) pools through dedicated NAD kinases. In mitochondria, NADK2 catalyzes the phosphorylation of NAD+ to NADP+ and, notably, can also phosphorylate NADH to NADPH. NADP+ generated by NADK2 or by NADPH oxidation is reduced to NADPH by enzymes including NNT, GLUD1, ME2, ALDH1L2, and IDH2. By contrast, using NADH as a substrate allows NADK2 to generate mitochondrial NADPH directly and rapidly, albeit at the expense of ATP. These reactions maintain a predominantly reduced NADPH pool that provides electrons for central mitochondrial processes. As mitochondria are a major source of oxidative stress due to reactive oxygen species (ROS) generated by the electron transport chain, they depend on NADPH for antioxidant protection. Mitochondrial NADPH fulfills this role by regenerating glutathione and thioredoxin via glutathione reductase and thioredoxin reductase, respectively, thereby supporting the detoxification of ROS. NADPH also fuels mitochondrial fatty acid synthesis (mtFAS) through enzymes such as MECR, contributing to protein lipoylation as well as mitochondrial translation, electron transport chain assembly, and citric acid cycle function.
== Methods == Several methods for cell lysis exist, sometimes used in combination. Examples include liquid homogenization, freeze thawing, and physical disruption such as sonication, or the use of hypotonic solutions that cause osmotic swelling and eventual bursting of the cell.
JINR did not propose a name after their first report claiming synthesis of element 105, which would have been the usual practice. This led LBL to believe that JINR did not have enough experimental data to back their claim. After collecting more data, JINR proposed the name bohrium (Bo) in honor of the Danish nuclear physicist Niels Bohr, a founder of the theories of atomic structure and quantum theory; they soon changed their proposal to nielsbohrium (Ns) to avoid confusion with boron. Another proposed name was dubnium. When LBL first announced their synthesis of element 105, they proposed that the new element be named hahnium (Ha) after the German chemist Otto Hahn, the "father of nuclear chemistry", thus creating an element naming controversy. In the early 1970s, both teams reported synthesis of the next element, element 106, but did not suggest names. JINR suggested establishing an international committee to clarify the discovery criteria. This proposal was accepted in 1974 and a neutral joint group formed. Neither team showed interest in resolving the conflict through a third party, so the leading scientists of LBL—Albert Ghiorso and Glenn Seaborg—traveled to Dubna in 1975 and met with the leading scientists of JINR—Georgy Flerov, Yuri Oganessian, and others—to try to resolve the conflict internally and render the neutral joint group unnecessary; after two hours of discussions, this failed. The joint neutral group never assembled to assess the claims, and the conflict remained unresolved.
Sources: en.wikipedia.org
Rimonabant (also known as SR141716; trade names Acomplia, Zimulti) is an anorectic antiobesity drug approved in Europe in 2006 but was withdrawn worldwide in 2008 due to serious neurological and psychiatric side effects; it was never approved in the United States. Rimonabant is an inverse agonist for the cannabinoid receptor CB1 and was first-in-class.
In relation to its selectivity for the AR, unlike steroidal antiandrogens (SAAs) such as CPA and megestrol acetate (MGA), bicalutamide does not interact importantly with other steroid hormone receptors (including the ERsTooltip estrogen receptors, PRsTooltip progesterone receptors, GRTooltip glucocorticoid receptor, or MRTooltip mineralocorticoid receptor), and in accordance, has no clinically relevant additional, off-target hormonal activity (estrogenic or antiestrogenic, progestogenic or antiprogestogenic, glucocorticoid or antiglucocorticoid, or mineralocorticoid or antimineralocorticoid). However, it has been reported that bicalutamide has weak affinity for the progesterone receptor (PR) (~100- to 500-fold lower than for the AR), where it acts as an antagonist (with only ~12-fold lower functional inhibition relative to the AR in one study). Hence, bicalutamide may have some antiprogestogenic activity, although the clinical relevance of this is unknown. Bicalutamide does not inhibit 5α-reductase and is not known to inhibit other enzymes involved in androgen steroidogenesis (e.g., CYP17A1). Although bicalutamide does not bind to the ERs, it can increase estrogen levels secondarily to blockade of the AR when used as a monotherapy in males, and for this reason, the medication can indirectly activate the ERs to a degree and hence have some indirect estrogenic effects in men.
=== CT and MRI scans === Imaging of the pituitary gland is important in confirming hypersomatotropism in cats where it is suspected. Showing a pituitary mass is important to establish a final diagnosis alongside clinical findings and hormonal findings. Knowing the size of the pituitary mass is also necessary to decide the best course of treatment. In the vast majority of cats with hypersomatropism, it is caused by an adenoma of the somatotrophic cells. Said adenoma is typically visible by the time a cat presents with symptoms; however, if pituitary imaging is performed during the early stages of the disease, it may still be small and difficult to recognise. Rarely CT/MRI imaging may not reveal anything, this may either due to a small size of the tumour or due to a different aetiology for the acromegaly. Rarely in humans with acromegaly, somatotrophic hyperplasia as the result of growth hormone releasing hormones, caused by a tumour. This aetiology has not been observed in cats; however, a cat with normal CT and MRI imaging, the histopathology showed—instead of adenoma—acidophilic proliferation.
Sources: en.wikipedia.org
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.
The DAC form carries a maleimide group that binds albumin and extends circulation time. The non-DAC form lacks this group and clears much faster. Both share the same receptor-binding core.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Activation raises cyclic AMP and promotes growth hormone release. Normal feedback pathways remain part of the response.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.